AUROPHARMA2025-07-012025-09-30AUROPHARMA2025-09-30AUROPHARMA2025-03-31AUROPHARMA2025-04-012025-09-30AUROPHARMA2025-07-012025-09-30in-capmkt:OtherExpenses1MemberAUROPHARMA2025-04-012025-09-30in-capmkt:OtherExpenses1MemberAUROPHARMA2025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1AUROPHARMA2025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss2AUROPHARMA2025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1AUROPHARMA2025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss2AUROPHARMA2025-07-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss1AUROPHARMA2025-04-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares524804AUROPHARMANOTLISTEDINE406A01037AUROBINDO PHARMA LIMITEDMain BoardEquity2025-04-012026-03-312025-11-052025-10-24INRMillionsQuarterlySecond quarterSingle segmentPharmaceutical products2025-11-0516:30:002025-11-0518:06:00trueCash Flow IndirectNot applicable2025-07-012025-09-30UnauditedConsolidated82857000000120590000084062900000250980000008460500000-1699000001277330000095240000042919000001991410000071320300000127426000000127426000004630300000-3524000004277900000084647000000001660000084813000005410700000138920000008484500000-320000013895200000-3200000580800000114.6114.610014.6114.61Notes: <BR> 1.The above unaudited consolidated financial results of Aurobindo Pharma Limited ("the Company") including its subsidiaries (collectively known as "the Group") and its associates and joint ventures have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. <BR> 2.The above unaudited consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of the Act and Companies (Indian Accounting Standards) Rules, 2015, as amended. <BR> 3.The above unaudited consolidated financial results of the Group as reviewed by the Audit Committee have been approved by the Board of Directors at its meeting held on November 5, 2025. The results for the quarter and half year ended September 30, 2025 have been reviewed by our statutory auditors. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter and half year ended September 30, 2025. <BR> 4.The Group operates in only one reportable segment viz., 'Pharmaceuticals ' in accordance with Ind AS 108, "Operating Segment". <BR> 5.During the quarter and half year ended September 30, 2025: <BR> (i) The Company, incorporated a step-down subsidiary, CuraTeQ Biologics B.V., Netherlands through CuraTeQ Biologics Private Limited, India (wholly owned subsidiary) on May 28, 2025. <BR> (ii) The Company, incorporated a step-down subsidiary, Cresedemo Pharma LLC through Aurobindo Pharma USA Inc., (wholly owned subsidiary) on June 13, 2025. <BR> (iii) The Company, incorporated a step-down subsidiary, Aurobindo Pharma (Malaysia) SDN. BHD. through Helix Healthcare B.V., The Netherlands, (wholly owned subsidiary) on September 17, 2025. <BR> (iv) The Company, incorporated a step-down subsidiary, CuraTeQ Biologics (Malta) Limited through CuraTeQ Biologics B.V., The Netherlands, (wholly owned subsidiary) on September 26, 2025. <BR> (v) Pharmacin B.V (wholly owned subsidiary of Agile Pharma BV) merged with Agile Pharma BV (wholly owned subsidiary of Helix Healthcare B.V., The Netherlands) w.e.f. July 1, 2025. <BR> (vi) Helix Healthcare B.V, The Netherlands, (wholly owned subsidiary) has transfered its 100% stake in CuraTeQ Biologics s.r.o., Czech Republic (wholly owned subsidiary) to CuraTeQ Biologics B.V, The Netherlands (wholly owned subsidiary) w.e.f. July 29, 2025. <BR> (vii) The Company, incorporated a step-down subsidiary, Aurobindo Pharma Chile SpA through Helix Healthcare B.V, (wholly owned subsidiary) on October 07, 2025. <BR> (viii) The Company, incorporated a step-down subsidiary, Eugia Pharma Chile SpA through Eugia Pharma B.V, (wholly owned subsidiary) on October 07, 2025. <BR> 6.During the current quarter, Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company, has entered into a definitive agreement to acquire 100% of membership interest in Lannett Company LLC. The proposed transaction is subject to certain regulatory approvals. Accordingly, no financial impact has arisen in the quarter and half year ended September 30, 2025. <BR> 2025-04-012025-09-30UnauditedConsolidated16153840000022550000001637934000005044960000016538500000-1207300000250613000001929900000834890000037881100000139002000000247914000000247914000009537500000-14336000008103900000016687500000000358000001672330000094691000002619240000016732000000-870000026201100000-8700000580800000128.8128.810028.8128.81Other Expenses19914100000Other Expenses37881100000132806800000303945000000636760000019678000000185537000000404800000226160000007120000055249000007857700000144092000008496600000238968900000111918800000102000005891110000054016400000348975000001663000002251700000150253200000182000002429690000028648710000000525456000000580800000349830400000350411200000-7260000035033860000010385200000000245560000012840800000372370000030025000000542900000201099000006440360000012792000004622680000047506000000294044000001413140000006232600000339880000040621000000155007500000001751174000005254560000001853100000-64817000003058000000-67260000000341300000055899000000761800000083489000001780000015117000000-20292000000396140000010900000173100000000054600000056900000011877800000366692000000007818600000028850600000005910000013070000000008710000013631600000000213550000000000000000001090000017619000000-8255300000-2223410000000000000348340000082681000005234000002321900000179590000000-9425900000-2809400000186200000-26232000005563790000053014700000Remeasurement of defined employee benefit liability-6100000Equity investment through other comprehensive income-net change in fair value88000002700000Remeasurement of defined employee benefit liability-28000000Equity investment through other comprehensive income-net change in fair value21100000-6900000700000-2100000Exchange differences on translating the financial statements of foreign operations54087000005408700000Exchange differences on translating the financial statements of foreign operations947390000094739000000054107000009469100000